88_CD
Hikma_NN
Pharmaceuticals_NN
PLC_NN
Principal_NN
Group_NN
companies_NN
Hikma_NN
Pharmaceuticals_NN
PLC_NN
West-ward_NN
Pharmaceutical_NN
Corporation_NOMZ
Medius_NN
House_NN
LG_NN
465_CD
Industrial_NN
Way_NN
West_NN
2_CD
Sheraton_NN
Street_NN
Eatontown_NN
,_,
New_NN
Jersey_NN
07724_CD
London_NN
W1F_NN
8BH_NN
USA_NN
UK_NN
Telephone_NN
:_:
1_CD
732 542 1191_CD
Telephone_NN
:_:
44 20 7479 4870_CD
4893_CD
Facsimile_NN
:_:
1_CD
732 542 6150_CD
Facsimile_NN
:_:
44 20 7760 2580_CD
Website_NN
:_:
www_NN
._.
com_NN
Hikma_NN
Farmacutica_NN
S._NN
A._NN
Estrada_NN
Rio_NN
Da_NN
Mo_NN
no._NN
._.
8_CD
From_PIN
1_CD
June_NN
2006_CD
Hikma_NN
Pharmaceuticals_NN
PLCs_NN
8A_NN
,_,
8BFervena_NN
address_NN
will_PRMD
be_VB
:_:
2705-906_CD
Terrugem_NN
SNT_NN
13_CD
Hanover_NN
Square_NN
Portugal_NN
London_NN
W1S_NN
1HW_NN
Telephone_NN
:_:
351 21 9608410_CD
UK_NN
Facsimile_NN
:_:
351 21 9615102_CD
Telephone_NN
:_:
44 20 7399 2760_CD
Facsimile_NN
:_:
44 20 7399 2761_CD
Hikma_NN
Pharmaceuticals_NN
Limited_NN
P._NN
O._NN
Box_NN
182400_CD
11118_CD
Amman_NN
Jordan_NN
Telephone_NN
:_:
962_CD
6_CD
5802900_CD
Facsimile_NN
:_:
962_CD
6_CD
5827102_CD
Advisers_NN
Auditors_NN
Legal_JJ
Advisers_NN
Deloitte_NN
&_CC
Touche_NN
LLP_NN
Ashurst_NN
Hill_NN
House_NN
Broadwalk_NN
House_NN
1_CD
Little_NN
New_NN
Street_NN
5_CD
Appold_NN
Street_NN
London_NN
EC4A_NN
4TR_NN
London_NN
EC2A_NN
2HA_NN
UK_NN
UK_NN
Brokers_NN
Public_NN
Relations_NOMZ
Citigroup_NN
Global_NN
Markets_NN
Limited_NN
Brunswick_NN
Group_NN
LLP_NN
Citigroup_NN
Centre_NN
16_CD
Lincolns_NN
Inn_NN
Fields_NN
Canada_NN
Square_NN
London_NN
WC2A_NN
3ED_NN
London_NN
E14_NN
5LB_NN
UK_NN
UK_NN
Merrill_NN
Lynch_NN
International_NN
Merrill_NN
Lynch_NN
Financial_NN
Centre_NN
2_CD
King_NN
Edward_NN
Street_NN
London_NN
EC1A_NN
1HQ_NN
UK_NN
Hikma_NN
Pharmaceuticals_NN
PLC_NN
Contents_VPRT
02_CD
Group_NN
at_PIN
a_DT
glance_NN
43_CD
Statement_NOMZ
of_PIN
Directors_NN
04_CD
Chairman_NN
and_PHC
responsibilities_NOMZ
Chief_NN
Executives_NN
review_NN
44_CD
Independent_NN
auditors_NN
report_VPRT [PUBV]
06_CD
Our_FPP1
strengths_NN
46_CD
Consolidated_NN
income_NN
statement_NOMZ
14_CD
Business_NOMZ
and_CC
financial_JJ
review_NN
47_CD
Consolidated_NN
statement_NOMZ
of_PIN
28_CD
Board_NN
of_PIN
Directors_NN
and_CC
recognized_VBN [PRIV]
income_NN
and_PHC
expenses_NN
senior_JJ
management_NOMZ
48_CD
Consolidated_NN
balance_NN
sheet_NN
30_CD
Report_NN
of_PIN
the_DT
Directors_NN
49_CD
Consolidated_NN
cash_NN
flow_NN
statement_NOMZ
32_CD
Board_NN
report_NN
on_PIN
corporate_JJ
50_CD
Notes_NN
to_PIN
the_DT
consolidated_JJ
financial_JJ
governance_NN
statements_NOMZ
35_CD
Audit_NN
Committee_NN
report_NN
81_CD
Hikma_NN
Pharmaceuticals_NN
PLC_NN
accounts_VPRT
37_CD
Board_NN
report_NN
on_PIN
remuneration_NOMZ
87_CD
Shareholder_NN
information_NOMZ
88_CD
Company_NN
information_NOMZ
Financial_NN
highlights_VPRT
Revenue_NN
Operating_GER
profit_NN
Profit_NN
attributable_JJ
$_$
million_CD
$_$
million_CD
to_PIN
shareholders_NN
$_$
million_CD
23.5_CD
%_NN
10.3_CD
%_NN
17.1_CD
%_NN
Diluted_JJ
earnings_GER
R&D_NN
costs_NN
per_PIN
share_NN
cents_NN
$_$
million_CD
14_CD
._.
1_CD
%_NN
70.7_CD
%_NN
2004_CD
figures_NN
restated_VBN
to_TO
reflect_VB [PRIV]
a_DT
change_NN
in_PIN
the_DT
presentation_NOMZ
of_PIN
the_DT
results_NN
of_PIN
our_FPP1
associate_NN
,_,
IPO_NN
costs_NN
and_PHC
Medicaid_NN
rebates_NN
._.
Further_JJ
information_NOMZ
is_VPRT [PASS]
given_VBN
in_PIN
Designed_JJ
and_CC
produced_VBN
by_PIN
Radley_NN
Yeldar_NN
._.
Note_VB [PRIV]
2_CD
to_PIN
the_DT
consolidated_JJ
financial_JJ
statements_NOMZ
._.
04_CD
04_CD
24.8_CD
212.4_CD
05_CD
28.3_CD
05_CD
262.2_CD
04_CD
04_CD
9.7_CD
62.7_CD
05_CD
05_CD
16.5_CD
69.2_CD
04_CD
37.5_CD
05_CD
43.9_CD
Hikma_NN
Pharmaceuticals_NN
PLC_NN
Annual_JJ
Report_NN
2005_CD
Hikma_NN
Pharmaceuticals_NN
PLC_NN
Hikma_NN
Pharmaceuticals_NN
PLC_NN
13_CD
Hanover_NN
Square_NN
Annual_JJ
Report_NN
2005_CD
London_NN
W1S_NN
1HW_NN
UK_NN
www_NN
._.
